NKTR ▲ +1.7% - Nektar Therapeutics
$NKTR - New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
30-SEP-2026 10:30 AM ET
Share this post
More filings for $NKTR
NKTR - Nektar Therapeutics - SEC Filing Update (28-SEP-2026) | ThinkSabio - Stocks SimplifiedSep 28, 2026NKTR ▼ -0.1% - Nektar TherapeuticsSep 28, 2026NKTR ▼ -4.0% - Nektar TherapeuticsSep 25, 2026NKTR ▼ -2.3% - Nektar TherapeuticsAug 28, 2026NKTR - Nektar Therapeutics - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026$NKTR SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026
View full $NKTR filing history →💬 Comments
Loading comments…
Leave a comment